Perry Genova most recently served as SVP of R&D at EndoQuest Robotics and Titan Medical USA. He has more than 25 years of ...

and other product initiatives such as OmniSphere and IV compounding robots. These factors, along with the improving financial condition of Omnicell's hospital client base, are said to position the ...

Dr. Genova will lead Omnicell’s technology strategy as the Company works to address pressing issues within medication and supply management across all care settings Medical device ...

Omnicell, Inc. OMCL has witnessed strong momentum in the past year. Shares of the company have risen 41.6% against a 11.3% decline of the industry during the same time frame. The S&P 500 composite ...

Omnicell OMCL underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light ...

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and ...

In the latest quarter, 4 analysts provided ratings for Omnicell OMCL, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the ...

Omnicell (NASDAQ:OMCL – Get Free Report) had its price objective cut by stock analysts at JPMorgan Chase & Co. from $44.00 to $36.00 in a research report issued to clients and investors on ...

Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the ...

OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning. Omnicell ( NASDAQ:OMCL ) Full ...